Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

207.88
-13.2700-6.00%
Pre-market: 206.14-1.7400-0.84%04:43 EDT
Volume:2.01M
Turnover:420.02M
Market Cap:44.56B
PE:-23.30
High:221.50
Open:221.50
Low:205.82
Close:221.15
52wk High:224.31
52wk Low:37.88
Shares:214.34M
Float Shares:184.00M
Volume Ratio:0.84
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:17.10
PE(LYR):-34.94

Loading ...

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 29

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says

MT Newswires Live
·
Aug 29

Movement Alert|Revolution Medicines, Inc. Falls 5.02% in Regular Trading, Profit-Taking Follows FDA Approval of Pancreatic Cancer Drug

Market Focus
·
Aug 28

UBS Adjusts Revolution Medicines Price Target to $265 From $220, Maintains Buy Rating

MT Newswires Live
·
Aug 28

Revolution Medicines is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 28

US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech

Deep News
·
Aug 28

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Dow Jones
·
Aug 28

Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says

MT Newswires Live
·
Aug 28

Revolution Medicines Stock (RVMD) Gets Price Target Hike on New Revenue-Generating Cancer Drug

TIPRANKS
·
Aug 28

Revolution Medicines is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Aug 27

Revolution Medicines price target raised to $320 from $230 at Evercore ISI

TIPRANKS
·
Aug 27

Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era

Reuters
·
Aug 27

RBC Capital Keeps Their Buy Rating on Revolution Medicines (RVMD)

TIPRANKS
·
Aug 27

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)

TIPRANKS
·
Aug 27

RBC Removes Speculative Risk From Revolution Medicines, Raises Price Target to $251 From $203, Keeps Outperform Rating

MT Newswires Live
·
Aug 27

Revolution Medicines price target raised to $280 from $195 at H.C. Wainwright

TIPRANKS
·
Aug 27

Revolution Medicines: Buy Rating Reiterated as FDA Approval and Strong Prelaunch Demand Support Unchanged $225 Price Target

TIPRANKS
·
Aug 27

U.S. Research Roundup-CrowdStrike, Nvidia, Macerich

Reuters
·
Aug 27

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230

THOMSON REUTERS
·
Aug 27